The Effects of Intensive Blood Pressure Control on Cardiovascular Outcomes Based on 10-Year ASCVD Risk Score: An Analysis of a Clinical Trial

Table 4

Serious adverse events in the intensive- and standard-treatment group.

ASCVD	Hypotension	Syncope	Bradycardia	Acute renal failure	Electrolyte abnormality
< 7.5%
Standard	Reference
Intensive	2.88 (0.58–14.29), 0.194	0.95 (0.23–3.82), 0.950	0.47 (0.04–5.20), 0.540	0.83 (0.30–2.31), 0.734	2.45 (0.95–6.32), 0.063
7.5%–10%
Standard	Reference
Intensive	2.55 (0.67–9.63), 0.166	2.33 (0.45–12.14), 0.306	0.89 (0.12–6.36), 0.908	4.92 (1.07–22.46), 0.040	1.59 (0.75–3.38), 0.222
10%–15%
Standard	Reference
Intensive	1.02 (0.46–2.28), 0.945	3.27 (1.30–8.20), 0.011	1.95 (0.87–4.38), 0.104	1.61 (0.86–3.01), 0.137	1.37 (0.75–2.52), 0.310
≥15%
Standard	Reference
Intensive	1.17 (01.20–2.44), 0.003	1.16 (0.84–1.60), 0.364	1.11 (0.78–1.57), 0.548	1.67 (1.28–2.16), <0.001	1.28 (0.97–1.68), 0.071
Total population
Standard	Reference
Intensive	1.66 (1.22–2.26), 0.001	1.33 (0.99–1.78), 0.051	1.18 (0.87–1.62), 0.279	1.65 (1.31–2.08), <0.001	1.37 (1.09–1.72), 0.006

Data were presented as hazard ratio (95% confidence interval), value. The bold value data indicates its significance. ASCVD: Atherosclerotic Cardiovascular Disease.